No Detail Found!

Time for change: conventional interferon regimes should not be the standard of care for management of pakistani genotype-3 in chronic hepatitis c

Author(s)
Muhammad Saleem Qureshi Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan
Musarrat Iqbal Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan
Ali Zohair Nomani Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan
Kamran Rasheed Department of Medicine, Khan Research Laboratories (KRL) Hospital, Islamabad-44000, Pakistan
Abstract
The aim of the present study was to determine the efficacy and side effect profile of conventional interferon alpha-2b plus ribavirin for treating chronic hepatitis C genotype-3 infections in Pakistan. The study was conducted on treating 220 treatment-naïve individuals at KRL Hospital with conventional interferon given for 6 months. Both the response and side effects were analyzed using simple descriptive statistics. Out of total cohort, 84.92% (169 out of 199) achieved end of treatment response (ETR) while 63.31% (126 out of 199) achieved sustained virological response (SVR). Leukopenia, gastrointestinal and miscellaneous systemic complaints were the most common adverse effects. In the context of a low ETR and SVR but a similar side effect profile as that of pegylated regimes, conventional therapy needs to be replaced with peg-interferon as the treatment of choice.
Publication Details
Page(s) 70-72
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 24, Issue: 1, Year: 2014

Request the full text from PASTIC

Keywords
Hepatitis C virus, conventional, Sustained virological response, Interferon, Side effects, Genotype 3, End of treatment response
0

Citations

0

Downloads

109

Views